ConductScience.org, home

Paper30116751

Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.

Liu J and 4 others. J Immunol Res, 2018. Cited by 38 papers, by iCite.

Cite this record

ConductScience Library. Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients. Papers, record 30116751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30116751

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.
PubMed
Journal
J Immunol Res
PubMed
Year
2018
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
38
iCite
Relative citation ratio, by iCite
1.23
iCite
Revised in PubMed
2021-01-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Liu JJiayu
2Li JJiaqian
3He MMin
4Zhang GLGeng-Linhttps://orcid.org/0000-0003-4156-4147
5Zhao QQiyihttps://orcid.org/0000-0003-0649-0437

Source PubMed

Download CSV of authors

Topics13

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CD4-Positive T-LymphocytesMajor topic
CD8-Positive T-LymphocytesMajor topic
Carcinoma, HepatocellularMajor topic
Liver NeoplasmsMajor topic
Receptors, ImmunologicMajor topic
Receptors, Tumor Necrosis Factor, Member 14Major topic
Adult
Aged
Female
Humans
Male
Middle Aged
Tumor Escape

Source PubMed

Download CSV of topics

References50

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
128484077Epstein-Barr Virus-Induced VEGF and GM-CSF Drive Nasopharyngeal Carcinoma Metastasis via Recruitment and Activation of Macrophages.Cancer Res2017https://conductscience.org/library/papers/28484077PubMed
228123898BTLA identifies dysfunctional PD-1-expressing CD4+ T cells in human hepatocellular carcinoma.Oncoimmunology2016https://conductscience.org/library/papers/28123898PubMed
324912948Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions.Hepatology2014https://conductscience.org/library/papers/24912948PubMed
426681673Regulation of PD-L1: a novel role of pro-survival signalling in cancer.Ann Oncol2016https://conductscience.org/library/papers/26681673PubMed
524531850Hepatocellular carcinoma: clinical frontiers and perspectives.Gut2014https://conductscience.org/library/papers/24531850PubMed
628290464Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer.Cell Res2017https://conductscience.org/library/papers/28290464PubMed
720307212Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.Annu Rev Immunol2010https://conductscience.org/library/papers/20307212PubMed
822445654The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.Curr Opin Pharmacol2012https://conductscience.org/library/papers/22445654PubMed
925610743Breaking the vicious cycle between breast cancer cells and tumor-associated macrophages.Oncoimmunology2014https://conductscience.org/library/papers/25610743PubMed
1025621841The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Curr Opin Immunol2015https://conductscience.org/library/papers/25621841PubMed
1126484443Immunological landscape and immunotherapy of hepatocellular carcinoma.Nat Rev Gastroenterol Hepatol2015https://conductscience.org/library/papers/26484443PubMed
1218650514Sorafenib in advanced hepatocellular carcinoma.N Engl J Med2008https://conductscience.org/library/papers/18650514PubMed
1326146815World-wide relative contribution of hepatitis B and C viruses in hepatocellular carcinoma.Hepatology2015https://conductscience.org/library/papers/26146815PubMed
1426895379Tumoral indoleamine 2, 3-dioxygenase 1 is regulated by monocytes and T lymphocytes collaboration in hepatocellular carcinoma.Oncotarget2016https://conductscience.org/library/papers/26895379PubMed
1525858804Immune checkpoint blockade: a common denominator approach to cancer therapy.Cancer Cell2015https://conductscience.org/library/papers/25858804PubMed
1619426226The CD160, BTLA, LIGHT/HVEM pathway: a bidirectional switch regulating T-cell activation.Immunol Rev2009https://conductscience.org/library/papers/19426226PubMed
1730116751Distinct Changes of BTLA and HVEM Expressions in Circulating CD4+ and CD8+ T Cells in Hepatocellular Carcinoma Patients.J Immunol Res2018https://conductscience.org/library/papers/30116751PubMed
1823470321Molecular mechanisms of T cell co-stimulation and co-inhibition.Nat Rev Immunol2013https://conductscience.org/library/papers/23470321PubMed
1920147741Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study.Ann Oncol2010https://conductscience.org/library/papers/20147741PubMed
2025605845Immune Checkpoint Blockade in Cancer Therapy.J Clin Oncol2015https://conductscience.org/library/papers/25605845PubMed

See all 50 referencesDownload CSV of references

Cited by26

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 38 citations.

PMIDTitleJournalYearIn PapersSource
41471273BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy.Pharmaceuticals (Basel)2025https://conductscience.org/library/papers/41471273PubMed
41319234CD160-Derived Peptide as a Bidirectional Inhibitor Toward Immune Checkpoints BTLA/HVEM and HVEM/LIGHT.J Med Chem2025https://conductscience.org/library/papers/41319234PubMed
41112836Immune checkpoint biology in hepatocellular carcinoma (Review).Oncol Lett2025https://conductscience.org/library/papers/41112836PubMed
40463377B and T lymphocyte attenuator (BTLA) and PD-1 pathway dual blockade promotes antitumor immune responses by reversing CD8+ T-cell exhaustion in non-small cell lung cancer.Front Immunol2025https://conductscience.org/library/papers/40463377PubMed
40243455Increased Herpesvirus Entry Mediator Expression on Circulating Monocytes and Subsets Predicts Poor Outcomes in Pancreatic Ductal Adenocarcinoma Patients.Int J Mol Sci2025https://conductscience.org/library/papers/40243455PubMed
40001057Assessing the causal association between 731 immunophenotypes and the risk of colorectal cancer: a Mendelian randomization study.BMC Cancer2025https://conductscience.org/library/papers/40001057PubMed
39956885CD28 Superfamily Costimulatory Molecules in Chronic Pain: Focus on Immunomodulation.Mol Neurobiol2025https://conductscience.org/library/papers/39956885PubMed
38939518Modulation of blood T cell polyfunctionality and HVEM/BTLA expression are critical determinants of clinical outcome in anti-PD1-treated metastatic melanoma patients.Oncoimmunology2024https://conductscience.org/library/papers/38939518PubMed
38835768The effect of gD-derived peptides on T cell immune response mediated by BTLA-HVEM protein complex in melanoma patients.Front Immunol2024https://conductscience.org/library/papers/38835768PubMed
38785930Herpesvirus Entry Mediator as an Immune Checkpoint Target and a Potential Prognostic Biomarker in Myeloid and Lymphoid Leukemia.Biomolecules2024https://conductscience.org/library/papers/38785930PubMed
38233898BTLA biology in cancer: from bench discoveries to clinical potentials.Biomark Res2024https://conductscience.org/library/papers/38233898PubMed
37041226BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia.Cancer Immunol Immunother2023https://conductscience.org/library/papers/37041226PubMed
34531847Soluble B7-CD28 Family Inhibitory Immune Checkpoint Proteins and Anti-Cancer Immunotherapy.Front Immunol2021https://conductscience.org/library/papers/34531847PubMed
34484870Combination checkpoint therapy with anti-PD-1 and anti-BTLA results in a synergistic therapeutic effect against murine glioblastoma.Oncoimmunology2021https://conductscience.org/library/papers/34484870PubMed
34385315Effects of sex and aging on the immune cell landscape as assessed by single-cell transcriptomic analysis.Proc Natl Acad Sci U S A2021https://conductscience.org/library/papers/34385315PubMed
33917094BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia.Cancers (Basel)2021https://conductscience.org/library/papers/33917094PubMed
33859648Roles of BTLA in Immunity and Immune Disorders.Front Immunol2021https://conductscience.org/library/papers/33859648PubMed
33564688Association of BTLA Polymorphisms with Susceptibility to Non-Small-Cell Lung Cancer in the Chinese Population.Biomed Res Int2021https://conductscience.org/library/papers/33564688PubMed
33365080High expression of HVEM is associated with improved prognosis in intrahepatic cholangiocarcinoma.Oncol Lett2021https://conductscience.org/library/papers/33365080PubMed
33238640Fragments of gD Protein as Inhibitors of BTLA/HVEM Complex Formation-Design, Synthesis, and Cellular Studies.Int J Mol Sci2020https://conductscience.org/library/papers/33238640PubMed

See all 26 cited byDownload CSV of cited by

Genes11

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30116751

GET https://conductscience.org/api/papers/v1/30116751/references?page=2